Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01769885

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

A Pilot Clinical Trial of Neoadjuvant Tivozanib in Localized Renal Cell Carcinoma

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Roswell Park Cancer Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies tivozanib before surgery in treating patients with localized kidney cancer. Tivozanib may stop the growth of tumor cells by blocking some of the growth factors needed for cell growth.

Detailed description

PRIMARY OBJECTIVES: I. To assess the feasibility of conducting a trial of tivozanib in the neoadjuvant setting of localized (completely resectable) renal cell cancer (RCC). SECONDARY OBJECTIVES: I. To evaluate the safety of tivozanib in the neoadjuvant setting. II. To compare the tissue before and after tivozanib for pharmacodynamic purposes (tumor infiltrating lymphocytes, myeloid derived suppressor cells, necrosis in the primary tumor after exposure to tivozanib). III. To assess the overall response rate of tivozanib in primary tumors and correlate the radiographic changes, if any, to histo-pathological changes in the pathology specimen post-nephrectomy. IV. To compare the various growth factors (vascular endothelial growth factor \[VEGF\], interleukin-8 \[IL-8\], placenta growth factor \[P1GF\]) at baseline and post treatment. V. To assess the nephrectomy rate after applying neoadjuvant tivozanib in this primarily resectable RCC population. OUTLINE: Patients receive tivozanib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy. After completion of study treatment, patients are followed up at 30 days.

Conditions

Interventions

TypeNameDescription
DRUGtivozanibGiven PO
PROCEDUREtherapeutic conventional surgeryUndergo nephrectomy

Timeline

Start date
2013-03-14
Primary completion
2013-06-14
Completion
2013-12-02
First posted
2013-01-17
Last updated
2022-08-15

Source: ClinicalTrials.gov record NCT01769885. Inclusion in this directory is not an endorsement.

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer (NCT01769885) · Clinical Trials Directory